Literature DB >> 8719515

Immunological parameters associated with antigenic competition in a multivalent footrot vaccine.

J D Hunt1, D C Jackson, P R Wood, D J Stewart, L E Brown.   

Abstract

A murine model for antigenic competition with multivalent D. nodosus pili vaccine has been established that parallels the phenomenon observed in sheep where levels of antibody, specific for any particular serogroup of pili, are significantly lower following vaccination in the presence of multiple serogroups of pili than with that serogroup alone. This competition was observed in both high and low responder strains of mice and was not dependent on the multiplicity of the antigens in the multivalent vaccine but could be observed with a large excess of a single heterologous serogroup. Competition was manifest by a reduction in the number of serogroup-specific antibody secreting cells elicited in response to vaccination. The antibody response to a single serogroup of pili reached a plateau at high doses and it was at these doses that antigenic competition was most pronounced, under conditions where both B- and T-cell responses were limiting. The limit in T-cell responsiveness was not imposed at the level of presentation of antigen. Pili-specific T cells were largely cross-reactive for different serogroups, and under conditions of limiting T-cell stimulation within a lymph node the available T cells would have to be shared between B cells specific for each serogroup of pili, which may in turn result in the decrease of serogroup-specific antibody induced following inoculation with the multivalent vaccine.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8719515     DOI: 10.1016/0264-410x(95)00145-q

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  The type IV fimbrial subunit gene (fimA) of Dichelobacter nodosus is essential for virulence, protease secretion, and natural competence.

Authors:  R M Kennan; O P Dhungyel; R J Whittington; J R Egerton; J I Rood
Journal:  J Bacteriol       Date:  2001-08       Impact factor: 3.490

2.  Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice.

Authors:  Vivek S Purohit; C Russell Middaugh; Sathyamangalam V Balasubramanian
Journal:  J Pharm Sci       Date:  2006-02       Impact factor: 3.534

Review 3.  A Quest for a Universal Plasma-Derived Antivenom Against All Elapid Neurotoxic Snake Venoms.

Authors:  Kavi Ratanabanangkoon
Journal:  Front Immunol       Date:  2021-04-23       Impact factor: 7.561

4.  Effective equine immunization protocol for production of potent poly-specific antisera against Calloselasma rhodostoma, Cryptelytrops albolabris and Daboia siamensis.

Authors:  Sompong Sapsutthipas; Poh Kuan Leong; Surasak Akesowan; Ronachai Pratanaphon; Nget Hong Tan; Kavi Ratanabanangkoon
Journal:  PLoS Negl Trop Dis       Date:  2015-03-16

5.  A Simple and Novel Strategy for the Production of a Pan-specific Antiserum against Elapid Snakes of Asia.

Authors:  Kavi Ratanabanangkoon; Kae Yi Tan; Sukanya Eursakun; Choo Hock Tan; Pavinee Simsiriwong; Teeraporn Pamornsakda; Witthawat Wiriyarat; Chaiya Klinpayom; Nget Hong Tan
Journal:  PLoS Negl Trop Dis       Date:  2016-04-08

6.  Induction of humoral immune response to multiple recombinant Rhipicephalus appendiculatus antigens and their effect on tick feeding success and pathogen transmission.

Authors:  Cassandra L Olds; Stephen Mwaura; David O Odongo; Glen A Scoles; Richard Bishop; Claudia Daubenberger
Journal:  Parasit Vectors       Date:  2016-09-02       Impact factor: 3.876

7.  Genomic heterogeneity of Dichelobacter nodosus within and between UK sheep flocks and between age groups within a flock.

Authors:  P L Davies; A M Blanchard; C E Staley; N J Bollard; T J Coffey; S Tötemeyer
Journal:  BMC Microbiol       Date:  2020-05-01       Impact factor: 3.605

8.  Massive immune response against IVIg interferes with response against other antigens in mice: A new mode of action?

Authors:  Laetitia Sordé; Sebastian Spindeldreher; Ed Palmer; Anette Karle
Journal:  PLoS One       Date:  2017-10-12       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.